AU778024B2 - Engineered cytotoxic ribonuclease - Google Patents

Engineered cytotoxic ribonuclease Download PDF

Info

Publication number
AU778024B2
AU778024B2 AU19184/00A AU1918400A AU778024B2 AU 778024 B2 AU778024 B2 AU 778024B2 AU 19184/00 A AU19184/00 A AU 19184/00A AU 1918400 A AU1918400 A AU 1918400A AU 778024 B2 AU778024 B2 AU 778024B2
Authority
AU
Australia
Prior art keywords
ribonuclease
amino acid
modified
steric hindrance
rnase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU19184/00A
Other languages
English (en)
Other versions
AU1918400A (en
Inventor
Ronald T. Raines
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wisconsin Alumni Research Foundation
Original Assignee
Wisconsin Alumni Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Research Foundation filed Critical Wisconsin Alumni Research Foundation
Publication of AU1918400A publication Critical patent/AU1918400A/en
Application granted granted Critical
Publication of AU778024B2 publication Critical patent/AU778024B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
AU19184/00A 1998-11-24 1999-11-22 Engineered cytotoxic ribonuclease Ceased AU778024B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/199,242 US6280991B1 (en) 1997-10-15 1998-11-24 Engineered cytotoxic ribonclease
US09/199242 1998-11-24
PCT/US1999/027670 WO2000031242A2 (en) 1998-11-24 1999-11-22 Engineered cytotoxic ribonuclease

Publications (2)

Publication Number Publication Date
AU1918400A AU1918400A (en) 2000-06-13
AU778024B2 true AU778024B2 (en) 2004-11-11

Family

ID=22736771

Family Applications (1)

Application Number Title Priority Date Filing Date
AU19184/00A Ceased AU778024B2 (en) 1998-11-24 1999-11-22 Engineered cytotoxic ribonuclease

Country Status (7)

Country Link
US (1) US6280991B1 (https=)
EP (1) EP1131417A2 (https=)
JP (2) JP4731015B2 (https=)
AU (1) AU778024B2 (https=)
CA (1) CA2351735C (https=)
IL (2) IL143036A0 (https=)
WO (1) WO2000031242A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7977079B2 (en) 2005-06-16 2011-07-12 Wisconsin Alumni Research Foundation Nucleic acid constructs encoding cytotoxic ribonuclease variants
US8048425B2 (en) 2005-06-16 2011-11-01 Wisconsin Alumni Research Foundation Cytotoxic ribonuclease variants

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2489446A1 (en) * 2002-06-14 2003-12-24 Wisconsin Alumni Research Foundation Ribonuclease zymogen design
WO2004085611A2 (en) * 2003-03-21 2004-10-07 The Research Foundation Of State University Of New York Model for mutually exclusive domain folding molecular switch
WO2005115477A2 (en) 2004-04-13 2005-12-08 Quintessence Biosciences, Inc. Non-natural ribonuclease conjugates as cytotoxic agents
CA2604243C (en) 2004-04-14 2015-11-24 Avirid, Inc. Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases
WO2007041361A1 (en) * 2005-09-30 2007-04-12 The Government Of The United States, As Represented By The Secretary Of Health And Human Services, National Institutes Of Health, Office Of Technology Transfer Modified recombinant anti-tumor rnase
EP2044097A4 (en) * 2006-06-23 2010-10-06 Quintessence Biosciences Inc Modified ribonucleases
US8298801B2 (en) 2006-07-17 2012-10-30 Quintessence Biosciences, Inc. Methods and compositions for the treatment of cancer
US8069251B2 (en) * 2007-06-01 2011-11-29 Adobe Systems Incorporated System and/or method for client-driven server load distribution
EP2205271B1 (en) * 2007-10-08 2014-05-21 Quintessence Biosciences, Inc. Compositions and methods for ribonuclease-based therapies
WO2009088992A2 (en) * 2008-01-07 2009-07-16 University Of Vermont And State Agricultural College Ribonuclease and thiazolidinedione compounds and their use in methods to treat cancer
US8029782B2 (en) 2008-10-01 2011-10-04 Quintessence Biosciences, Inc. Therapeutic ribonucleases
KR101934923B1 (ko) 2009-11-02 2019-04-10 유니버시티 오브 워싱톤 스루 이츠 센터 포 커머셜리제이션 치료학적 뉴클레아제 조성물 및 방법
PH12013502441B1 (en) 2011-04-29 2019-02-08 Univ Washington Therapeutic nuclease compositions and methods
PL3063275T3 (pl) 2013-10-31 2020-03-31 Resolve Therapeutics, Llc Terapeutyczne fuzje nukleaza-albumina i sposoby
ES2971441T3 (es) * 2016-05-06 2024-06-05 Biodynamic Res Foundation Composición farmacéutica que contiene un fármaco macromolecular
JP7308034B2 (ja) 2016-07-01 2023-07-13 リゾルブ セラピューティクス， エルエルシー 最適化二重ヌクレアーゼ融合物および方法
BR112020003670A2 (pt) 2017-08-22 2020-09-01 Sanabio, Llc receptores de interferon solúveis e usos dos mesmos
US11286469B2 (en) 2017-11-09 2022-03-29 Wisconsin Alumni Research Foundation Combination chemotherapy for the treatment of cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9694698A (en) * 1997-10-15 1999-05-03 Wisconsin Alumni Research Foundation Human ribonuclease a with reduced ribonuclease inhibitor affinity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840840A (en) 1990-04-17 1998-11-24 The United States Of America As Represented By The Department Of Health And Human Services Selective RNase cytotoxic reagents
US5389537A (en) 1994-01-21 1995-02-14 Wisconsin Alumni Research Foundation Nuclease having altered specificity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9694698A (en) * 1997-10-15 1999-05-03 Wisconsin Alumni Research Foundation Human ribonuclease a with reduced ribonuclease inhibitor affinity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LELAND PA ET AL. (1998) PROC NATL. ACAD. SCI USA 95:10407-12 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7977079B2 (en) 2005-06-16 2011-07-12 Wisconsin Alumni Research Foundation Nucleic acid constructs encoding cytotoxic ribonuclease variants
US8048425B2 (en) 2005-06-16 2011-11-01 Wisconsin Alumni Research Foundation Cytotoxic ribonuclease variants
US8247190B2 (en) 2005-06-16 2012-08-21 Wisconsin Alumni Research Foundation Method for delivering cytotoxic activity to cells
US8293872B2 (en) 2005-06-16 2012-10-23 Wisconsin Alumni Research Foundation Cytotoxic ribonuclease variants
US8524480B2 (en) 2005-06-16 2013-09-03 Wisconsin Alumni Research Foundation Cytotoxic ribonuclease variants

Also Published As

Publication number Publication date
JP2002532067A (ja) 2002-10-02
CA2351735C (en) 2011-09-13
JP2011078428A (ja) 2011-04-21
WO2000031242A2 (en) 2000-06-02
JP4731015B2 (ja) 2011-07-20
US6280991B1 (en) 2001-08-28
IL143036A0 (en) 2002-04-21
CA2351735A1 (en) 2000-06-02
AU1918400A (en) 2000-06-13
IL143036A (en) 2009-06-15
WO2000031242A3 (en) 2000-11-23
EP1131417A2 (en) 2001-09-12

Similar Documents

Publication Publication Date Title
AU778024B2 (en) Engineered cytotoxic ribonuclease
US5840296A (en) Engineered cytotoxic ribonuclease A
CN102300987A (zh) 膜型-1基质金属蛋白抑制剂及其用途
DE69731463T2 (de) Rekombinante ribonuklease proteine
US6045793A (en) Recombinant ribonuclease proteins
EP1446163A2 (en) Multidrug multiligand conjugates for targeted drug delivery
WO2005036176A1 (en) Cell surface molecules as markers and therapeutic agents against kidney cancers
AU2002301972B2 (en) Human Ribonuclease A with Reduced Ribonuclease Inhibitor Affinity
US6869604B1 (en) Recombinant anti-tumor RNAse
CN103865899B (zh) 具有vegfr2/kdr受体特异性的融合毒素及其编码基因与应用
KR100409264B1 (ko) 세포내 신호전달을 교란시키는 합성 펩티드
AU755147B2 (en) Recombinant anti-tumor RNASE
KR102557016B1 (ko) 암 치료를 위한 cd47 바인더 및 리포좀 복합체
Pulido et al. Preparation of ribonuclease S domain-swapped dimers conjugated with DNA and PNA: Modulating the activity of ribonucleases
CA2401916A1 (en) Recombinant anti-tumor rnase
EP1277838A1 (en) Recombinant anti-tumor RNASE
HK1238557A1 (en) Antibody-urease conjugates for therapeutic purposes

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired